Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FS016
- Development stage
- Preclinical
- Lead developer
- Foreseen Biotechnology
01
Overview
FS016 is a preclinical-stage therapeutic candidate being developed by Foreseen Biotechnology for the treatment of solid tumors. Discovered using the company's proprietary AI-driven translational platform, which integrates high-throughput proteomics and clinical data to identify novel targets, FS016 is part of a broader pipeline of oncology assets. While the specific biological target and modality (such as a monoclonal antibody or antibody-drug conjugate) have not been publicly disclosed, the asset is currently progressing through early preclinical development, including lead optimization and IND-enabling studies.
Beyond the preview
Go deeper on FS016.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FS016.